Japan approves Eli Lilly's Alzheimer's treatment Kisunla for early symptomatic Alzheimer's.

Eli Lilly's Alzheimer's treatment, Kisunla (donanemab-azbt), has received approval from Japan's Ministry of Health for use in early symptomatic Alzheimer's, including mild cognitive impairment and mild dementia. This follows its initial approval in the U.S. in July 2024. Kisunla aims to reduce amyloid plaque buildup, which is linked to cognitive decline, and has shown positive results in clinical studies.

September 24, 2024
12 Articles